Abstracts tagged "Atherosclerosis"

Abstract Number: 1523 • 2015 ACR/ARHP Annual Meeting
Ischemia Modified Albumin Levels in Rheumatoid Arthritis
Ali Ugur Uslu¹, Adem Kucuk², Sevket Balta³, Sevket Arslan⁴, Levent Tekin⁵, Sami Kucuksen⁶, Aysun Toker⁷ and Mehmet Kayrak⁸, ¹Internal Medicine, Eskisehir Military Hospital, Eskisehir, Turkey, ²Necmettin Erbakan U Meram T F, Necmettin Erbakan U Meram T F, Konya, Turkey, ³Cardiology, Eskisehir Military Hospital, Eskisehir, Turkey, ⁴Allergy and Clinical Immunology, Necmettin Erbakan University, Konya, Turkey, ⁵Physical Medicine and Rehabilitation, Beyhekim State Hospital, Konya, Turkey, ⁶MD, kONYA, Turkey, ⁷Biochemistry, Necmettin Erbakan University, Konya, Turkey, ⁸Necmettin Erbakan University, Division of Cardiology, Konya, Turkey
Background/Purpose: Cardiovascular diseases, among which atherosclerotic heart disease, are known to be one of the most important mortality and morbidity causes in patients with Rheumatoid…
Abstract Number: 2003 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Is Characterized By Endothelial Progenitor Dysfunction and a Type I Interferon Signature
Robert C. Grenn¹, Srilakshmi Yalavarthi², Paula L. Bockenstedt³ and Jason S. Knight², ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI
Background/Purpose: Patients with primary antiphospholipid syndrome (APS) are at risk for endothelial dysfunction and accelerated atherosclerosis. In systemic lupus erythematosus (SLE), there is a well-established…
Abstract Number: 1536 • 2015 ACR/ARHP Annual Meeting
Sensorineural Hearing Impairment and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients without Traditional Cardiovascular Risk Factors
Hector Macias Reyes¹, Sergio Duran-Barragan^2,3, Cynthia Cardenas Contreras⁴, Cesar Chavez Martin⁴, Eduardo Gomez², Rosa Navarro Hernandez², Jorge Aguilar Arreola^2,5, Paul Perez-Cruz^2,5, Carlos Yanowsky Gonzalez² and Monica Vazquez-Del Mercado^2,5, ¹1. Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ²Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Instituto de Investigación en Reumatología y del Sistema Musculoesquelético, Guadalajara, Mexico, ³Clinica de Investigación en Reumatología y Obesidad, Guadalajara, Mexico, ⁴Hospital Civil Fray Antonio Alcalde, Guadalajara, Mexico, ⁵Servicio de Reumatología, División de Medicina Interna, Hospital Civil Dr. Juan I. Menchaca, Guadalajara, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is characterized by inflammation of the synovial membrane of the diarthrodial joints which include arthrodesis of the middle ear, (incudomalleolar and…
Abstract Number: 2128 • 2015 ACR/ARHP Annual Meeting
The Role of Insulin Resistance in the Development of Premature Atherosclerosis in Patients with Rheumatoid Arthritis
Gorica Ristic¹, Vesna Subota², Toplica Lepic³, Dejana Stanisavljevic⁴, Branislava Glisic¹, Milan Petronijevic¹, Arsen Ristic⁵ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Department of Neurology, Military Medical Academy, Belgrade, Serbia, ⁴Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia, ⁵Department of Cardiology, Clinical Center of Serbia & Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Accelerated atherosclerosis in rheumatoid arthritis (RA) is well established but the role of insulin resistance in RA pts without diabetes or metabolic syndrome remains…
Abstract Number: 1548 • 2015 ACR/ARHP Annual Meeting
Comparison of 5 Cardiovascular Risk Calculators in a Hispanic Rheumatoid Arthritis Cohort
Alberto Cardenas-de La Garza¹, Raymundo Vera-Pineda², Dionicio A. Galarza-Delgado¹, Jose Ramon Azpiri-Lopez³, Iris J. Colunga-Pedraza¹, Griselda Serna-Peña⁴ and Mario Alberto Garza-Elizondo¹, ¹Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ²Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ³Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Internal Medicine, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in RA. Management and stratification of ASCVD in RA patients is still a matter…
Abstract Number: 2343 • 2015 ACR/ARHP Annual Meeting
Impact of Colchicine Use on the Development of Incident Coronary Artery Disease
Susanna Jeurling¹, Daria Crittenden², Mark C. Fisher³, Binita Shah⁴, Steven P. Sedlis⁴, Craig T. Tenner⁵, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Division of Rheumatology, NYU School of Medicine, New York, NY, ²Rheumatology, NYU-HJD, New York, NY, ³Rheumatology, New York Univ-HJD, New York, NY, ⁴NYU School of Medicine, Division of Cardiology, New York, NY, ⁵Medicine, NYU School of Medicine, New York, NY, ⁶NYU School of Medicine, Division of Rheumatology, New York, NY, ⁷Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Patients with gout experience both inflammation and increased risk of cardiovascular disease (CVD). Studies suggest that colchicine reduces myocardial infarction (MI) risk, but whether…
Abstract Number: 1572 • 2015 ACR/ARHP Annual Meeting
Plasma Apolipoprotein B48 Levels in Patients with Rheumatoid Arthritis: Evaluating Novel Cardiovascular Risk Factors
Deborah van Breukelen-van der Stoep¹, Derkjen van Zeben¹, Marijke de Vries², Boudewijn Klop², Noelle van der Meulen², Gert Jan van de Geijn³, Hans Janssen³, Pedro Valdivielso⁴, José Rioja⁴, José Ramirez-Bollero⁴, Mieke Hazes⁵, Erwin Birnie^6,7 and Manuel Castro Cabezas⁸, ¹Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ²Department of Internal Medicine, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ³Department of Clinical Chemistry, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁴Department of Internal Medicine and Dermatology, Hospital Virgen de la Victoria, Malaga, Spain, ⁵Department of Rheumatology, Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, ⁶Statistics and Education, Sint Franciscus Gasthuis, Rotterdam, Netherlands, ⁷Insitute of Health Policy and Management, Erasmus University, Rotterdam, Netherlands, ⁸Department of Internal Medicine, Sint Francicscus Gasthuis, Rotterdam, Netherlands
Background/Purpose: Chylomicrons, with apolipoprotein (apo) B48 as a structural protein, induce leukocyte and complement activation and contribute to atherosclerosis. ApoB48 is higher in conditions associated…
Abstract Number: 2630 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Carotid Plaque: 10-Year Follow-up
Raymundo Vera-Pineda¹, Alberto Cardenas-de La Garza², Dionicio A. Galarza-Delgado², Jose Ramon Azpiri-Lopez³, Iris J. Colunga-Pedraza², Jorge Munoz De Hoyos², Griselda Serna-Peña⁴, Brenda B Tovar-Jasso², Mario Alberto Garza-Elizondo² and Gerardo Ornelas⁵, ¹Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ³Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Internal Medicine, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Radiology, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: The main cause of mortality in patients with rheumatoid arthritis (RA) is atherosclerotic cardiovascular disease (ASCVD). RA patients have a 10-year decrease in life…
Abstract Number: 1573 • 2015 ACR/ARHP Annual Meeting
Plasma Pentraxin 3 Concentration Is Associated with Progression of Radiographic Joint Damage but Not with Carotid Atherosclerosis in Female Patients with Rheumatoid Arthritis: Results from a 3-Year Prospective Study
Yu Asanuma¹, Yuki Shimada², Yoshimi Aizaki¹, Kazuhiro Yokota¹, Noritsune Kouzu³, Yoshitake Takebayashi⁴, Hisashi Noma⁴, Shinichi Kawai⁵ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Saitama Medical University, Saitama, Japan, ³Kouzu Orthopaedic Clinic, Chiba, Japan, ⁴The Institute of Statistical Mathematics, Tokyo, Japan, ⁵Div of Rheum/dept of Int Med, Toho Uni Sch of Med, Tokyo, Japan
Background/Purpose: Pentraxin 3 (PTX3) plays an important role in inflammation, immunity, and atherosclerosis. Plasma PTX3 level is recognized as a marker that responds to local…
Abstract Number: 2814 • 2015 ACR/ARHP Annual Meeting
IL-10 May Mitigate Cardiovascular Risk in Psoriatic Arthritis Via an Anti-Atherosclerotic Effect on Cellular Cholesterol Transport
Lucas McCaffrey¹, Iryna Voloshyna², Michael J. Littlefield², Eduard Zhurov³, Steven E. Carsons⁴, Elise Belilos⁵, Kristina Belostocki⁶, Lois Bonetti⁷, Gary Rosenblum⁶ and Allison B. Reiss², ¹Medicine, Division of Rheumatology, Winthrop-University Hospital, Mineola, NY, ²Medicine, Winthrop University Hospital, Mineola, NY, ³Winthrop-University Hospital, Mineola, NY, ⁴Rheumatology, Allergy and Immunology, Winthrop University Hospital, Mineola, NY, ⁵Winthrop University Hospital, Mineola, NY, ⁶Rheumatology, Winthrop University Hospital, Mineola, NY, ⁷Rheum & Immun, Winthrop University Hospital, Mineola, NY
Background/Purpose: The increased risk of major adverse cardiovascular events (MACE) in patients who suffer from systemic inflammatory conditions such as Rheumatoid Arthritis (RA), Systemic Lupus…
Abstract Number: 1593 • 2015 ACR/ARHP Annual Meeting
Telomere Length and Cardiovascular Risk in Rheumatoid Arthritis
Michelle J. Ormseth¹, Joseph F. Solus², Annette M. Oeser³, Aihua Bian⁴, Tebeb Gebretsadik⁴, Ayumi Shintani⁵, Paolo Raggi⁶ and C Michael Stein⁵, ¹Department of Medicine, Division of Rheumatology, Vanderbilt University, Nashville, TN, ²Clinical Pharmacology, Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt University, Nashville, TN, ⁴Biostatistics, Vanderbilt University, Nashville, TN, ⁵Vanderbilt University, Nashville, TN, ⁶Emory University, Atlanta, GA
Background/Purpose: Telomeres protect against DNA damage and shorten with each cell division; their length may be a marker of cardiovascular and overall biological aging. Patients…
Abstract Number: 3057 • 2015 ACR/ARHP Annual Meeting
Can We Differentiate Takayasu’s Arteritis from Atherosclerosis Using Carotid Artery Doppler Usg?
Serdal Ugurlu¹, Fatma Ela keskin², Firat Cetinkaya³, Melike Melikoglu¹, Vedat Hamuryudan⁴, Izzet Fresko⁴, Pinar Kadioglu² and Emire Seyahi⁴, ¹Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Turkey, Istanbul, Turkey, ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Colormed Radiology Center, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: Clinicians can have difficulty in making differential diagnosis between Takayasu and atherosclerosis. This is especially true when laboratory evaluations and FDG PET are inconclusive.…
Abstract Number: 172 • 2015 ACR/ARHP Annual Meeting
Prospective Assessment of Carotid Intima Media Thickness in Relation to Activity of the Disease in Patients with Rheumatoid Arthritis
Bozena Targonska-Stepniak¹, Mariusz Piotrowski¹, Robert Zwolak² and Maria Majdan³, ¹Rheumatology and Connective Tissue Diseases, Medical University of Lublin, Poland, Lublin, Poland, ²Rheumatologyand Connective Tissue Diseases, Medical University of Lublin, Lublin, Poland, ³Department of Rheumatology and Connective Tissue Diseases, Medical University in Lublin, Poland, Lublin, Poland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease that is complicated by accelerated atherosclerosis associated with the risk of adverse cardiovascular (CV) events and…
Abstract Number: 1602 • 2015 ACR/ARHP Annual Meeting
Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
Gorica Ristic¹, Vesna Subota², Petar Ristic³, Dejana Stanisavljevic⁴, Arsen Ristic⁵, Branislava Glisic¹, Milan Petronijevic¹ and Dusan Stefanovic¹, ¹Department of Rheumatology and Clinical Immunology, Military Medical Academy, Belgrade, Serbia, ²Institute of Medical Biochemistry, Military Medical Academy, Belgrade, Serbia, ³Department of Endocrinology, Military Medical Academy, Belgrade, Serbia, ⁴Institute of Medical Statistics, Belgrade University School of Medicine, Belgrade, Serbia, ⁵Department of Cardiology, Clinical Center of Serbia & Belgrade University School of Medicine, Belgrade, Serbia
Background/Purpose: Insulin resistance (IR) is increased and β-cell function impaired in rheumatoid arthritis (RA). The aim of this study was to evaluate whether treatment with…
Abstract Number: 257 • 2015 ACR/ARHP Annual Meeting
Investigation of the Arterial Stiffness and Associated Factors in Patients with Familial Mediterranean Fever
Mustafa Cakar¹, Muharrem Akhan², Tolga Doğan², Gurhan Taskin³, Kadir Ozturk⁴, Muhammet Cinar¹, Erol Arslan² and Sedat Yılmaz¹, ¹Rheumatology, Gulhane Medical Faculty, Ankara, Turkey, ²Internal Medicine, Gulhane Medical Faculty, Ankara, Turkey, ³Internal Medicine Intensive Care, Gulhane Medical Faculty, Ankara, Turkey, ⁴Gastroenterology, Gulhane Medical Faculty, Ankara, Turkey
Background/Purpose: Arterial stiffness represents the viscoelastic properties of the vessel wall. It occurs as a result of known atherosclerotic risk factors such as hypertension, diabetes…

« Previous Page
1
…
8
9
10
11
12
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.